相似文献
1
Fostering next generation transplant physicians.
Blood Cell Ther. 2024 May 17;7(2):56-63. doi: 10.31547/bct-2024-004. eCollection 2024 May 25.
2
Activity and Capacity Profile of Transplant Physicians and Centers in Australia and New Zealand.
Biol Blood Marrow Transplant. 2018 Jan;24(1):169-174. doi: 10.1016/j.bbmt.2017.09.011. Epub 2017 Sep 28.
3
Allogeneic transplant physician and center capacity in the United States.
Biol Blood Marrow Transplant. 2011 Jul;17(7):956-61. doi: 10.1016/j.bbmt.2011.03.008. Epub 2011 Apr 12.
4
Urgent Time to Allogeneic Hematopoietic Cell Transplantation: A National Survey of Transplant Physicians and Unrelated Donor Search Coordinators Facilitated by the Histocompatibility Advisory Group to the National Marrow Donor Program.
Biol Blood Marrow Transplant. 2019 Dec;25(12):2501-2506. doi: 10.1016/j.bbmt.2019.08.002. Epub 2019 Aug 13.
5
Updates in hematopoietic cell transplant and cellular therapies that enhance the risk for opportunistic infections.
Transpl Infect Dis. 2023 Nov;25 Suppl 1:e14101. doi: 10.1111/tid.14101. Epub 2023 Jul 18.
6
Prevalence of hematopoietic cell transplant survivors in the United States.
Biol Blood Marrow Transplant. 2013 Oct;19(10):1498-501. doi: 10.1016/j.bbmt.2013.07.020. Epub 2013 Jul 30.
7
Extracorporeal Membrane Oxygenation Candidacy in Pediatric Patients Treated With Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy: An International Survey.
Front Oncol. 2021 Dec 22;11:798236. doi: 10.3389/fonc.2021.798236. eCollection 2021.
8
Returning to Work Following Hematopoietic Cell Transplantation: The Survivor's Perspective.
Transplant Cell Ther. 2024 Jun;30(6):612.e1-612.e12. doi: 10.1016/j.jtct.2024.03.028. Epub 2024 Mar 30.
9
Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation.
Transplant Cell Ther. 2023 Feb;29(2):123.e1-123.e10. doi: 10.1016/j.jtct.2022.11.019. Epub 2022 Nov 26.
10
A Decision Support Tool for Allogeneic Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: Acceptability and Usability Study.
JMIR Form Res. 2021 Oct 28;5(10):e30093. doi: 10.2196/30093.
本文引用的文献
1
Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians.
Lancet Haematol. 2023 Jul;10(7):e492-e494. doi: 10.1016/S2352-3026(23)00180-1.
2
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
N Engl J Med. 2023 Jun 22;388(25):2338-2348. doi: 10.1056/NEJMoa2215943.
3
Endemic or regionally limited bacterial and viral infections in haematopoietic stem-cell transplantation recipients: a Worldwide Network for Blood and Marrow Transplantation (WBMT) Review.
Lancet Haematol. 2023 Apr;10(4):e284-e294. doi: 10.1016/S2352-3026(23)00032-7.
4
Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research.
Transplant Cell Ther. 2023 Jun;29(6):346.e1-346.e10. doi: 10.1016/j.jtct.2023.03.007. Epub 2023 Mar 15.
5
EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation.
Bone Marrow Transplant. 2023 May;58(5):498-505. doi: 10.1038/s41409-023-01922-8. Epub 2023 Jan 31.
6
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial.
Transplant Cell Ther. 2023 Mar;29(3):208.e1-208.e6. doi: 10.1016/j.jtct.2022.12.017. Epub 2022 Dec 27.
7
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy.
Blood Adv. 2023 Jul 11;7(13):3192-3198. doi: 10.1182/bloodadvances.2022008294.
8
Combining the Disease Risk Index and Hematopoietic Cell Transplant Co-Morbidity Index provides a comprehensive prognostic model for CD34-selected allogeneic transplantation.
Adv Cell Gene Ther. 2021 Jan;4(1). doi: 10.1002/acg2.103. Epub 2020 Sep 25.
9
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma.
Leukemia. 2023 Jan;37(1):154-163. doi: 10.1038/s41375-022-01739-2. Epub 2022 Nov 5.
10
Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation.
Blood Adv. 2022 Nov 22;6(22):5898-5907. doi: 10.1182/bloodadvances.2022007381.
Zotero 插件